PURPOSE: Although it is generally accepted that consolidation therapy for neuroblastoma includes irradiation of the primary site and any remaining metaiodobenzylguanidine (MIBG)-avid metastatic sites, limited information has been published regarding the efficacy of this approach. METHODS AND MATERIALS: Thirty patients with high-risk neuroblastoma were treated at 1 radiation therapy (RT) department after receiving 5 cycles of induction chemotherapy and resection. All patients had at least a partial response after induction therapy, based upon international neuroblastoma response criteria. The primary sites were treated with 24 to 30 Gy whereas the MIBG-avid metastatic sites were treated with 24 Gy. RT was followed by high-dose chemotherapy with autologous stem cell rescue and 6 months of cis-retinoic acid. RESULTS: The 5-year progression-free survival (PFS) and overall survival (OS) rates were 48% and 59%, respectively. The 5-year locoregional control at the primary site was 84%. There were no differences in locoregional control according to degree of primary surgical resection. The 5-year local control rate for metastatic sites was 74%. The 5-year PFS rates for patients with 0, 1, 2, and >3 postinduction MIBG sites were 66%, 57%, 20%, and 0% (P<.0001), respectively, whereas 5-year OS rates were 80%, 57%, 50%, and 0%, respectively (P<.0001). CONCLUSIONS: RT to the primary site and postinduction MIBG-positive metastatic sites was associated with 84% and 74% local control, respectively. The number of MIBG-avid sites present after induction chemotherapy and surgery was predictive of progression-free and overall survival.
PURPOSE: Although it is generally accepted that consolidation therapy for neuroblastoma includes irradiation of the primary site and any remaining metaiodobenzylguanidine (MIBG)-avid metastatic sites, limited information has been published regarding the efficacy of this approach. METHODS AND MATERIALS: Thirty patients with high-risk neuroblastoma were treated at 1 radiation therapy (RT) department after receiving 5 cycles of induction chemotherapy and resection. All patients had at least a partial response after induction therapy, based upon international neuroblastoma response criteria. The primary sites were treated with 24 to 30 Gy whereas the MIBG-avid metastatic sites were treated with 24 Gy. RT was followed by high-dose chemotherapy with autologous stem cell rescue and 6 months of cis-retinoic acid. RESULTS: The 5-year progression-free survival (PFS) and overall survival (OS) rates were 48% and 59%, respectively. The 5-year locoregional control at the primary site was 84%. There were no differences in locoregional control according to degree of primary surgical resection. The 5-year local control rate for metastatic sites was 74%. The 5-year PFS rates for patients with 0, 1, 2, and >3 postinduction MIBG sites were 66%, 57%, 20%, and 0% (P<.0001), respectively, whereas 5-year OS rates were 80%, 57%, 50%, and 0%, respectively (P<.0001). CONCLUSIONS: RT to the primary site and postinduction MIBG-positive metastatic sites was associated with 84% and 74% local control, respectively. The number of MIBG-avid sites present after induction chemotherapy and surgery was predictive of progression-free and overall survival.
Authors: Atmaram S Pai Panandiker; Chris Beltran; Catherine A Billups; Lisa M McGregor; Wayne L Furman; Andrew M Davidoff Journal: Pediatr Blood Cancer Date: 2012-09-28 Impact factor: 3.167
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: Prog Clin Biol Res Date: 1994
Authors: Karen J Marcus; Robert Shamberger; Heather Litman; Daniel von Allmen; Stephen A Grupp; Cheryl Medeiros Nancarrow; Joel Goldwein; Holcombe E Grier; Lisa Diller Journal: J Pediatr Hematol Oncol Date: 2003-12 Impact factor: 1.289
Authors: Heather G Gatcombe; R B Marcus; Howard M Katzenstein; Mourad Tighiouart; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-11 Impact factor: 7.038
Authors: Howard M Katzenstein; Susan L Cohn; Richard M Shore; Dianna M E Bardo; Paul R Haut; Marie Olszewski; Jennifer Schmoldt; Dachao Liu; Alfred W Rademaker; Morris Kletzel Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: F Berthold; B Hero; B Kremens; R Handgretinger; G Henze; F H Schilling; M Schrappe; T Simon; C Spix Journal: Cancer Lett Date: 2003-07-18 Impact factor: 8.679
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-27 Impact factor: 7.038
Authors: Dana L Casey; Ken L Pitter; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 7.038
Authors: Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038
Authors: Joseph C Easton; Sergio Gomez; Peter H Asdahl; J Michael Conner; Alcira B Fynn; Claudia Ruiz; Rohit P Ojha Journal: Pediatr Transplant Date: 2016-05-27
Authors: Alexander F Bagley; David R Grosshans; Nancy V Philip; Jennifer Foster; Mary Frances McAleer; Susan L McGovern; Yasmin Lassen-Ramshad; Anita Mahajan; Arnold C Paulino Journal: Pediatr Blood Cancer Date: 2019-05-02 Impact factor: 3.167